Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis : Working With SOLTI to Launch Phase 3 Trial on Kisqali in Patients With Advanced Breast Cancer

09/20/2021 | 05:59am EDT


© MT Newswires 2021
All news about NOVARTIS AG
10/22PRESS RELEASE : FDA approves Roche's Susvimo, a -2-
DJ
10/22Creatd Shares Jump After Unit Signs Alexis LaRue
DJ
10/21BIONTECH : Shares Rise After Data Shows Efficacy of COVID-19 Vaccine's Booster Dose
MT
10/21GLOBAL MARKETS LIVE : Tesla, Unilever, Paypal, Elliott, Novartis...
10/21NOVARTIS : COVID-19 news feed
PU
10/21Novartis Signs New Deal With BioNTech to Support Production of Covid-19 Vaccine
MT
10/21Novartis Expands Fill-and-Finish Deal with BioNTech for COVID-19 Jabs
MT
10/21NOVARTIS : signs new initial agreement with BioNTech to support fill and finish of the mRN..
PU
10/21NOVARTIS : extends deal to make Pfizer/BioNTech vaccines
RE
10/20Novartis in New Agreement With BioNTech to Help Manufacture Covid-19 Vaccine
DJ
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2021 51 997 M - -
Net income 2021 9 905 M - -
Net Debt 2021 23 507 M - -
P/E ratio 2021 18,7x
Yield 2021 3,86%
Capitalization 189 B 189 B -
EV / Sales 2021 4,09x
EV / Sales 2022 3,83x
Nbr of Employees 109 000
Free-Float 87,0%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 84,63 $
Average target price 101,98 $
Spread / Average Target 20,5%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-7.30%189 189
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979